Korea Private Health Insurance: The 36 Million Problem

Massage Bills Beat Cancer Bills

Something strange happened in Korean hospitals last year. Claims for manual therapy — the hands-on physiotherapy Koreans call dosu chiryo — reached ₩2.7 trillion, roughly $1.9 billion. Meanwhile, claims for cancer, strokes and heart disease combined came to ₩2.6 trillion. In other words, Korea private health insurance paid more for back rubs than for the country’s deadliest illnesses.

That single comparison explains why the product Koreans call silson has become the most argued-about contract in Korean finance. Nearly 40 million people hold one. The system lost ₩1.87 trillion in 2025 alone. As a result, regulators launched the biggest redesign in its history in May 2026, and doctors have been fighting them ever since.

Foreigners rarely hear about any of this. Expat guides describe Korea’s national health system as cheap, fast and universal — which it is. However, that description covers only half the picture. Underneath the public system sits a second, privately run layer that most Korean households treat as essential. Locals call it silson, short for “actual-loss” insurance. Understanding it is the difference between a ₩30,000 hospital visit and a ₩300,000 one.

What Silson Insurance Actually Does

Korea’s National Health Insurance Service, or NHIS, covers everyone legally resident in the country. Consequently, a consultation costs a few dollars and an MRI costs a fraction of American prices. So far, so famous.

Nevertheless, the NHIS does not cover everything. Korean medicine divides treatments into two buckets: geuptyeo (covered) and bigeuptyeo (non-covered). Covered treatments come with a fixed national price and a small patient share. Non-covered treatments, by contrast, have no fixed price at all. Hospitals set their own rates, and patients pay the full amount.

This is where Korean indemnity insurance enters. For a monthly premium, a private insurer reimburses most of what the patient paid out of pocket — including much of the non-covered bill. For instance, a shoulder injection that costs ₩150,000 at the counter might cost the patient ₩30,000 after reimbursement. Naturally, the product became wildly popular. Koreans often describe it as the “second health insurance,” and the nickname is accurate: at the end of 2025, insurers held 36.22 million silson contracts in a country of 51 million people.

That popularity is precisely the problem. Because insurers absorb the non-covered bill, neither patient nor hospital has much reason to care what a non-covered treatment costs. Hospitals therefore raised prices, invented new packages, and recommended more sessions. Patients, in turn, accepted them. The bill landed somewhere else entirely.

The Numbers Behind Korea Private Health Insurance

The 2025 figures, published by financial regulators in mid-2026, make the strain hard to miss.

Premium income rose 10% to roughly ₩18 trillion. Payouts, however, rose faster — up 11.4% to about ₩17 trillion. The resulting underwriting loss reached ₩1.87 trillion, a 15.6% widening from ₩1.62 trillion the year before. Most importantly, the loss ratio crossed a symbolic line, climbing from 99.3% to 101.0%.

A loss ratio above 100% means the product pays out more than it collects before a single administrative cost is counted. In addition, it means every existing policyholder can expect premium increases, because Korean indemnity insurance is repriced regularly.

Where did the money go? Non-covered treatment absorbed ₩9.7 trillion, or 57.1% of all claims. Within that pile, three categories stand out:

Musculoskeletal manual therapy: ₩2.7 trillion (15.8% of all claims)
Cancer and cardio-cerebrovascular disease: ₩2.6 trillion
Non-covered outpatient injections: ₩1 trillion (6.1%)

Certain procedures grew even faster. Robotic surgery claims jumped 72.4% year on year. Prostate ligation rose 64.6%. High-intensity focused ultrasound, or HIFU, climbed 46%. None of these are fringe treatments; rather, they are exactly the sort of high-margin, loosely priced services that flourish when someone else pays.

The 9% Who Take 80%

Averages hide the real story here. Roughly 70% of Koreans hold a silson policy, yet the money flows to a narrow group. Industry analysis puts it starkly: about 9% of policyholders receive close to 80% of all payouts. Conversely, a large share of the insured never file a claim in a given year at all.

That concentration is not automatically a scandal. Insurance exists to move money toward people who need care, and some of those heavy claimers are seriously ill. Nevertheless, the mix matters. When the biggest single category is manual therapy rather than oncology, the pattern starts to look less like risk-pooling and more like a subscription to discounted physiotherapy.

Koreans notice. Complaints about “insurance shopping” — booking sessions because they are nearly free — surface constantly in domestic media. Meanwhile, quiet policyholders watch their premiums climb to fund treatment they never use. Politically, that resentment is what makes reform possible at all.

Four Generations, Four Different Products

Here is the part that confuses even Koreans. Silson insurance is not one product. Instead, it is four, sold in successive waves, each with different rules — and all of them still active.

First generation (sold until 2009). Extremely generous. Many policies reimbursed 100% of out-of-pocket costs with almost no limits. Roughly 6.18 million contracts remain, about 17.1% of the total.

Second generation (2009–2017). Introduced a patient share of 10–20%. It is still the largest block by far, with 14.94 million contracts, or 41.2%.

Third generation (2017–2021). Split non-covered treatments such as manual therapy and injections into separate riders with their own limits. Around 7.83 million contracts, or 21.6%.

Fourth generation (2021–2026). Added a bonus-malus system: heavy claimers pay more at renewal, light claimers pay less. It now holds 6.41 million contracts, 17.7% of the market, having overtaken the first generation in roughly four years.

Loss ratios tell a surprising story. The third generation runs at 120.3% — the worst of the four. Its successor, the fourth, sits at 115.1%. Meanwhile the first generation, despite famously loose terms, posts 102.3%, and the second generation actually makes money at 93.1%.

Why would newer, stricter products lose more? Because the strictest designs attracted the sickest and most claim-aware buyers, while the loosest ones were sold decades ago to a younger, healthier cohort that has been paying premiums ever since. Meanwhile, hospitals adapted to each new rulebook faster than regulators could rewrite it.

The Fifth Generation Arrives

On 6 May 2026, sixteen insurers — seven life companies and nine non-life companies — began selling the fifth generation of Korean indemnity insurance. The redesign, coordinated by the Ministry of Health and Welfare, is blunt about its logic: cut what the system pays for, and cut what the customer pays.

On price, the new product is dramatically cheaper. Premiums run roughly 30% below a comparable fourth-generation policy and more than 50% below first- and second-generation policies. Regulators published one illustration that circulated widely: a customer in their sixties paying ₩178,000 a month could drop to about ₩100,000 on the new selective plan, and into the ₩20,000 range once conversion discounts apply from November 2026.

On coverage, the cuts are equally blunt. Annual reimbursement for non-severe, non-covered treatment falls from ₩50 million to ₩10 million. Patient coinsurance rises to as much as 50%. Furthermore, several categories leave the policy altogether:

Manual therapy and extracorporeal shockwave therapy
Non-covered injections
Selected “new medical technologies” without established evidence

In exchange, the fifth generation adds coverage that the old products skipped — notably pregnancy and childbirth benefits, plus benefits tied to developmental disorders. Given Korea’s birth rate, that addition is as much industrial policy as insurance design.

The open question is adoption. Existing policyholders cannot be forced to switch, and the most expensive generations are also the ones whose holders benefit most from staying put. Therefore, the reform’s success depends on whether discounts are large enough to pull tens of millions of people voluntarily out of contracts they have held for fifteen years.

Nobody Wants to Sell It

Reform assumed insurers would push the new product hard. Instead, the launch landed with a thud.

The reasons are commercial rather than ideological. Firstly, a cheaper policy earns a smaller commission, and Korean agents work under a rule capping first-year commissions at 1,200% of the monthly premium. Cut the premium by a third, and the agent’s payday shrinks with it. Secondly, insurers expect the fifth generation to drag on short-term earnings even if it improves loss ratios later, because new contracts carry acquisition costs before they generate margin.

There is a third, more awkward reason. The buyback scheme meant to tempt first- and second-generation holders into switching does not take effect until November 2026, and its terms were still unsettled through the summer. Selling aggressively before then risks complaints from customers who converted early and lost out.

Consumers, meanwhile, have run their own math. Holders of the oldest policies face a steep jump in out-of-pocket costs that a 50% discount does not fully offset. Holders of third- and fourth-generation contracts find the coverage cut larger than the premium cut. Roughly 1.58 million pre-2013 contracts sit on the buyback target list, but nobody can be compelled to move.

As a result, the biggest reform Korea private health insurance has ever attempted now rests on a product that neither the seller nor the buyer is enthusiastic about.

The ₩43,850 Fight

Reforming Korea private health insurance meant touching something insurers cannot control: the price hospitals charge.

From July 2026, manual therapy moved into a new category called “managed benefit.” The mechanics matter. First, the price became national and fixed: ₩43,850 for a 30-minute session, down from an average of roughly ₩110,000. Second, the patient now pays 95% of that price directly. Third, sessions are capped at 15 per year, extendable to 24 when a doctor documents need. Finally, patients must complete at least four sessions of basic physical therapy over two weeks before manual therapy begins, except in urgent cases such as post-surgical joint restriction.

Read those rules together and the intent is obvious. The government did not ban manual therapy. Instead, it made the treatment cheap, capped, and mostly self-funded — removing the arbitrage that made it a ₩2.7 trillion line item.

Doctors reacted furiously. Clinics argued that a nationally fixed price for a hands-on treatment ignores differences in duration, skill and equipment. Rehabilitation and pain-medicine practices, many of which built their business models around non-covered therapy, warned of closures. Patient groups split: some welcomed the lower sticker price, while others objected to paying 95% of a treatment they had previously claimed back almost in full.

Insurers, predictably, want the model extended. Their argument is that non-covered pricing without any national benchmark will simply migrate to the next loosely regulated treatment. Research from the Korea Insurance Research Institute has made a similar structural point for years: the leak is not one procedure, but the absence of price discipline in an entire category.

Why Silson Reform Keeps Failing

Korea has now redesigned silson insurance five times in about twenty years. Each redesign tightened the rules. Each time, claims found a new channel.

The pattern is consistent. When first-generation policies paid everything, spending concentrated in general outpatient care. After the second generation introduced patient shares, non-covered injections grew. When the third generation capped injections and manual therapy through riders, spending shifted toward newer procedures. Now, with manual therapy priced and capped, the categories growing fastest are robotic surgery, HIFU and other technology-intensive treatments that no rulebook has caught up with yet.

Two structural facts keep the cycle running. Firstly, Korean hospitals earn thin margins on covered treatment, whose prices the Health Insurance Review and Assessment Service sets nationally. Non-covered treatment is where profit lives. Secondly, Korea has an unusually high density of clinics competing for the same patients, which pushes providers toward whatever service currently carries the best margin.

Consequently, reform that targets a single procedure behaves like squeezing a balloon. Unless the underlying incentive changes, the air simply moves.

The Paperwork Problem Nobody Solved

There is one more twist, and it is oddly mundane. For decades, claiming on Korean indemnity insurance meant collecting paper receipts from the hospital and uploading them yourself. To fix that, regulators launched an app called Silson24, which sends medical documents straight from the clinic to the insurer.

The results have been underwhelming. As of July 2026, Silson24 handled 458,388 claims against a monthly average of 10.02 million — about 4.6%. Registered users reached 4.54 million out of 34.8 million insured, or 13.0%.

The bottleneck sits with providers. Only 40.5% of eligible medical institutions have connected their systems. Among smaller clinics the figure drops to 18.1%; dental clinics sit at 10.0%, and traditional Korean medicine hospitals at just 2.7%. Geography compounds the gap: Seoul residents file 8.0% of claims digitally, while the figure in South Gyeongsang Province is 2.8%.

For foreign residents, this matters more than it sounds. Paper claims in Korean are exactly the sort of friction that causes expats to skip reimbursement entirely — and to conclude, wrongly, that the policy was worthless.

Should Foreigners Buy Korea Private Health Insurance?

Short answer: sometimes. Here is how to think about it.

You are already covered by NHIS. Foreign residents on most long-term visas must enroll, either through an employer or as a local subscriber. That coverage is genuinely strong for serious illness, surgery and hospitalization. For many expats staying a year or two, it is enough on its own.

Silson is a top-up, not a substitute. Private policies reimburse your out-of-pocket share plus part of the non-covered bill. Therefore, the value depends entirely on how often you use treatments that NHIS does not cover — physiotherapy, dermatology, certain imaging, injections, and a growing list of elective procedures.

Eligibility is real but uneven. Insurers can sell to foreign residents who hold a valid alien registration card and NHIS enrollment. In practice, underwriting varies by company, visa type and length of stay. Some insurers decline short-term visas outright. Consequently, it pays to ask two or three companies rather than one.

Read the generation, not the brochure. If someone offers to “upgrade” an existing policy, check which generation you hold and which you would move to. The fifth generation is cheaper but covers far less non-covered treatment. For a healthy person in their thirties, that trade is usually sensible. For someone in regular physiotherapy, it may not be.

Budget for the new rules. Since July 2026, manual therapy costs about ₩43,850 per session with 95% paid by you. That is roughly $31 — cheap by international standards, but no longer reimbursable the way it once was.

Use Silson24 if your clinic supports it. Ask at reception before your appointment. If the clinic is not connected, keep the paper receipts and the itemized statement; insurers require both.

Watch the elective-treatment market. Korea’s non-covered sector is also what makes the country a destination for medical tourism, dental implants and aesthetic procedures. Prices there are transparent precisely because nobody is reimbursing them.

What Comes Next

Three things are worth watching over the next year.

Firstly, conversion numbers. Discounts on fifth-generation switching begin in November 2026, and the take-up rate will reveal whether 36 million policyholders can be moved by price alone.

Secondly, the managed-benefit list. If regulators extend the manual-therapy model to non-covered injections or newer procedures, the confrontation with clinics will escalate sharply. Doctors are already stretched by the fallout from Korea’s medical school expansion fight, and another pricing battle would land on an exhausted profession.

Thirdly, demographics. Korea’s over-65 population keeps expanding, and older policyholders claim far more than younger ones. Even a perfectly designed product struggles against that arithmetic, which is why Korean indemnity insurance sits at the center of the country’s broader silver economy calculations.

For anyone living in Korea, though, the practical takeaway is simpler. The public system remains one of the best deals in the developed world. The private layer on top of it is being rewritten in real time, and the version you buy in 2027 will look nothing like the one your Korean colleague bought in 2012. Ask which generation they hold. Then ask what it costs them now — the answer is usually more interesting than the brochure.

For newcomers, our guide to the Korean healthcare system covers NHIS enrollment, hospital tiers and emergency care.